Zetagen Therapeutics, a privately held clinical-stage biopharmaceutical company pioneering first-of-its-kind targeted therapies for both primary and metastatic breast cancer, announced today that its ...

Case study demonstrated resolution of lytic lesions, significant reduction in pain and prevention of fracture. ZetaMet™ is a first-of-its kind molecular pathway designed to suspend cancer, inhibit ...

A recent report details the first reported case of an osteolytic lesion in polycythemia vera and reviews current literature on osteolytic lesions in myeloproliferative neoplasms (MPNs) overall.

RECIST was developed in 2000 by the National Cancer Institute, European Organization for Research and Treatment of Cancer, and National Cancer Institute of Canada, with revision to RECIST 1.1 in 2009 ...

Metastasis Stage, Adjuvant Treatment, and Residual Tumor Are Prognostic Factors for Medulloblastoma in Children: Conclusions From the Children's Cancer Group 921 Randomized Phase III Study PURPOSE: To ...

SYRACUSE, N.Y.--(BUSINESS WIRE)--Central New York Biotech Accelerator (CNYBAC) — Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing breakthrough ...

For most people living with multiple myeloma, bone pain tops the list of symptoms. No wonder, given that the disease causes cancerous plasma cells to build up in bone marrow (the soft tissue in bones) ...

A 17-year-old girl presented to a hospital orthopedics department in Vietnam due to pain in her left hip joint, which she noted had been getting worse over the past month. Neither her personal nor her ...